MS Patients are always interested when it comes to brain health or something that can combat their symptoms. A few studies have now come out concerning omega-3 fatty acids and how they can benefit these patients. What Are Omega-3 Fatty Acids? Omega-3 fatty acids contain two compounds, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are believed to decrease certain immune and inflammatory reactions in the body. Since multiple sclerosis stems from a dysfunctio

As is customary, every Friday we will provide you with 3 easy to prepare MS friendly recipes to try this coming weekend! Macadamia-Crusted Sriracha Ranch Salmon Looking to do something more exciting with salmon fillets? Make my Macadamia-Crusted Sriracha Ranch Salmon, one of the brand new recipes from the "Kinda Ready" section of our brand-new cookbook, Ready or Not! http://nomnompaleo.com/2017/08/22/2017082220170822macadamia-crusted-sriracha-ranch-salmon Madras Chicken Salad

A new study has found that as multiple sclerosis (MS) worsens, costs associated with the disease increases. The study, “New insights into the burden and costs of multiple sclerosis in Europe,” was published in the Multiple Sclerosis Journal. The study consisted of more than 16,000 patients in 16 European countries. Researchers obtained their information from patient self-reporting. Patients used the Kurtzke’s Expanded Disability Status Sale (EDSS) to assess the severity of th

A new study showed that multiple sclerosis (MS) patients taking Tecfidera, or dimethyl fumarate, were more productive at work than those on Copaxone or beta-interferon therapies. Tecfidera also proved to increase patients’ quality of life. The study was published in Neurology and Therapy, and was titled “Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients.” The study consisted of patient

Alkermes is funding a Phase 3 clinical trial evaluating the effects of its ALKS 8700 therapy on the gastrointestinal tracts of relapsing-remitting multiple sclerosis (RRMS) patients, compared to Tecfidera (dimethyl fumarate), according to a news release by the National Multiple Sclerosis Society. ALKS 8700, an orally administrated form of monomethyl fumarate, is still under clinical development. Although similar to Tecfidera, ALKS 8700 is designed to treat produce differentia

Topas Therapeutics and Eli Lilly and Company are teaming up to develop compounds that could be used to treat inflammatory and autoimmune diseases, such as multiple sclerosis and diabetes. The compounds, based on a Topas technology platform, will be aimed at restoring immune tolerance. Immune tolerance refers to the immune system being unresponsive to certain antigens — for instance, the body’s own proteins. Without immune tolerance, the body can generate an excessive immune r